We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Welcome to Episode #178 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
In this episode, Tracey is joined by Zacks Senior Strategist, Kevin Cook, to discuss what the top hedge fund managers were buying, or selling, in the first quarter of 2019.
Every year, Tracey and Kevin have discussed the 13-F filings, which money managers with over $100 million under management, must file with the SEC forty-five days after the end of the quarter. The 13-F reveals what stocks were bought, and sold, during the quarter.
Berkshire Hathaway Buys Amazon
The first big surprise, which was revealed by Warren Buffett himself ahead of the Berkshire Hathaway annual meeting, was that Berkshire added its first position in Amazon (AMZN - Free Report) in the first quarter.
Berkshire bought almost $1 billion worth, which sounds like a lot but is only 0.43% of Berkshire’s portfolio, ranking it at 27th in the portfolio.
By comparison, Apple is now a 23.7% position in the portfolio worth $47 billion.
But unlike Apple, Amazon isn’t normally considered a value stock so this purchase was controversial, to say the least.
Making Bets on China
Who’s afraid of a trade war?
Not David Tepper of Appaloosa whose largest position continues to be Micron (MU - Free Report) at 22.8% of his portfolio.
He also sold Alibaba (BABA - Free Report) shares last year, only to buy them again in 2019. Is he that confident that a trade agreement is coming?
Is Concentration Paying Off?
While Tepper is concentrated in Micron, and Buffett is a believer in Apple, Bill Ackman at Pershing Square has gone all in on the consumer.
Ackman’s largest position is Chipotle (CMG - Free Report) which is now 19.7% of his portfolio. That is followed in a close second by Restaurant Brands (QSR - Free Report) at 17.8% and then Lowe’s at 13.6%.
That’s nearly 50% of his total portfolio in just 3 consumer names, but it has paid off as Chipotle shares are up 64% year-to-date.
But is that much concentration too risky, even for a professional investor?
Big fund managers made some other interesting bets in the first quarter that might leave you scratching your head.
Find out what those trades are and much more in this week’s podcast.
[In full disclosure, the author of this article owns shares of AMZN in her personal portfolio.]
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Top Fund Managers in Q1: Risky Trades or Smart Stock Bets?
Welcome to Episode #178 of the Zacks Market Edge Podcast.
Every week, host and Zacks stock strategist, Tracey Ryniec, will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.
In this episode, Tracey is joined by Zacks Senior Strategist, Kevin Cook, to discuss what the top hedge fund managers were buying, or selling, in the first quarter of 2019.
Every year, Tracey and Kevin have discussed the 13-F filings, which money managers with over $100 million under management, must file with the SEC forty-five days after the end of the quarter. The 13-F reveals what stocks were bought, and sold, during the quarter.
Berkshire Hathaway Buys Amazon
The first big surprise, which was revealed by Warren Buffett himself ahead of the Berkshire Hathaway annual meeting, was that Berkshire added its first position in Amazon (AMZN - Free Report) in the first quarter.
Berkshire bought almost $1 billion worth, which sounds like a lot but is only 0.43% of Berkshire’s portfolio, ranking it at 27th in the portfolio.
By comparison, Apple is now a 23.7% position in the portfolio worth $47 billion.
But unlike Apple, Amazon isn’t normally considered a value stock so this purchase was controversial, to say the least.
Making Bets on China
Who’s afraid of a trade war?
Not David Tepper of Appaloosa whose largest position continues to be Micron (MU - Free Report) at 22.8% of his portfolio.
He also sold Alibaba (BABA - Free Report) shares last year, only to buy them again in 2019. Is he that confident that a trade agreement is coming?
Is Concentration Paying Off?
While Tepper is concentrated in Micron, and Buffett is a believer in Apple, Bill Ackman at Pershing Square has gone all in on the consumer.
Ackman’s largest position is Chipotle (CMG - Free Report) which is now 19.7% of his portfolio. That is followed in a close second by Restaurant Brands (QSR - Free Report) at 17.8% and then Lowe’s at 13.6%.
That’s nearly 50% of his total portfolio in just 3 consumer names, but it has paid off as Chipotle shares are up 64% year-to-date.
But is that much concentration too risky, even for a professional investor?
Big fund managers made some other interesting bets in the first quarter that might leave you scratching your head.
Find out what those trades are and much more in this week’s podcast.
[In full disclosure, the author of this article owns shares of AMZN in her personal portfolio.]
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>